

Bleomycin

Essential medicine status

General description

Bleomycin is an antineoplastic agent that inhibits DNA metabolism and is used in the treatment of lymphomas and solid tumours.

INN

Bleomycin

ATC codes

[L01DC01](#)

Medicine type

Chemical agent

EML status history

First added in 1979 ([TRS 641](#)) for [Hodgkin lymphoma](#)

Added in 1979 ([TRS 641](#)) for [Kaposi sarcoma of unspecified primary site](#)

Added in 1979 ([TRS 641](#)) for [Germ cell tumour of testis](#)

Added in 1979 ([TRS 641](#)) for [Other specified malignant neoplasms of the ovary](#)

Added in 1979 ([TRS 641](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Wikipedia

[Bleomycin](#)

DrugBank

[Bleomycin](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

[Hodgkin lymphoma](#) [Kaposi sarcoma of unspecified primary site](#) [Germ cell tumour of testis](#) [Other specified malignant neoplasms of the ovary](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)